Ernexa Therapeutics Inc.
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
ERNA$2.01-2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| For the six months ended June 30, | ||||
|---|---|---|---|---|
| 2026 · 2025 | ||||
| Cash flows from operating activities: | ||||
| Net loss | $(9,515) | $(11,341) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation and amortization | 17 | 35 | ||
| Stock-based compensation | 629 | 870 | ||
| Amortization of right-of-use asset | 113 | 89 | ||
| Impairment of goodwill | 2,044 | - | ||
| Issuance of common stock to consultant for services | 120 | 93 | ||
| Accrued interest expense | - | 22 | ||
| Forward sales contract expense | - | 5,847 | ||
| Issuance of common stock in connection with settlement | - | 69 | ||
| Change in fair value of warrant liabilities | - | (1) | ||
| Gain on extinguishment of contingent liability | (41) | - | ||
| Changes in operating assets and liabilities: | ||||
| Other receivables | 12 | 283 | ||
| Prepaid expenses and other current assets | (379) | (137) | ||
| Other non-current assets | 85 | 1 | ||
| Accounts payable and accrued expenses | 365 | (463) | ||
| Operating lease liability | (115) | (91) | ||
| Due from related party | 750 | - | ||
| Due to related party | (500) | - | ||
| Other liabilities | (1) | 127 | ||
| Net cash used in operating activities | (6,416) | (4,597) | ||
| Cash flows from investing activities: | ||||
| Purchase of property and equipment | (5) | - | ||
| Cash used in investing activities | (5) | - | ||
| Cash flows from financing activities: | ||||
| Gross proceeds received from the sale of common stock, prefunded warrants and Milestone Warrants in public offering | 10,480 | - | ||
| Proceeds received from the issuance of common stock and prefunded warrants | - | 4,929 | ||
| Fees related to public offering | (939) | - | ||
| Proceeds received from notes payable | - | 2,250 | ||
| Gross proceeds received from the exercise of prefunded warrants | 20 | 4 | ||
| Fee related to the exercise of prefunded warrants from public offering | (2) | - | ||
| Issuance of common stock under ATM | 6 | - | ||
| Net cash provided by financing activities | 9,565 | 7,183 | ||
| Net increase in cash | 3,144 | 2,586 | ||
| Cash at beginning of period | 1,884 | 1,729 | ||
| Cash at end of period | $5,028 | $4,315 | ||
| Cash paid during the period for: | ||||
| Interest | $ | - | $4 | |
| Income taxes | $ | - | $3 | |
| Supplemental disclosure of non-cash investing and financing activities: | ||||
| Offset of related party notes payable principal with related party receivable related to issuance of common stock and prefunded warrants | $ | - | $2,250 | |
| Reclassification of forward sales contract to equity upon issuance of common stock | $ | - | $5,847 | |
| Issuance of common stock to Series A preferred stockholders in lieu of cash dividends | $8 | $8 | ||
| Remeasurement of ROU asset and lease liability | $26 | $ | - | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.